Research Training Group 2154 - Materials for Brain

Project 8: Vivian Adamski

Neuroimplants for glioblastoma therapy

Glioblastoma multiforme (GBM) is known to be one of the most aggressive primary brain tumors in adults and characterized by varied morphological features and the presence of heterogeneous cell populations within a single tumor. The current golden-standard therapy includes surgery as well as radio- and concomitant chemotherapy with Temozolomide. However, regarding the tumor heterogeneity the median survival of treated patients ranges from 12 to 15 months accompanied with various side effects of the chemotherapy. Therefore, alternative therapeutics, new treatment schemes and especially local treatment approaches to reduce side effects combined with enhanced treatment efficiency are mandatory to improve treatment outcome and patient’s life.
In this project, we evaluate the efficiency of different alternative chemotherapeutic compounds for GBMs of different molecular subtypes, concerning both single drug treatment and combinatory sequential-treatment strategies in connection with the golden-standard therapeutic Temozolomide. Moreover, in collaboration with the material scientists, appropriate materials as well as material-chemotherapeutic combinations are designed for local treatment strategies. Finally, most sufficient combinations are analyzed regarding their properties in GBM therapy using a tumor-specific co-culture model with healthy brain cells in vitro most likely resembling tumor resection characteristics of the in vivo situation.